|
1. Scully C, Bagan
J. Oral mucosal diseases: erythema multiforme. Br J
Oral Maxillofac
Surg. 2008;46:90-5.
https://doi.org/10.1016/j.bjoms.2007.07.202
PMid:17767983
|
|
|
|
2. Katz J, Livneh
A, Shemer J, Danon YL, Peretz B. Herpes
simplex associated erythema
multiforme
(HAEM): a clinical therapeutic dilemma.
Pediatr Dent. 1999;2:359-62.
PMid:10509338
|
|
|
|
|
3. Roujeau
JC, Stern RS. Severe adverse cutaneous reactions
to drugs. N Engl J Med. 1994;331:1272-85.
https://doi.org/10.1056/NEJM199411103311906
PMid:7794310
|
|
|
|
|
4. Ayangco
L, Rogers III RS. Oral manifestations
of erythema multiforme. Dermatol Clin. 2003;21:195-205.
https://doi.org/10.1016/S0733-8635(02)00062-1
PMid:12622281
|
|
|
|
|
5. Stewart MG, Duncan III NO,
Franklin DJ, Friedman EM, Sulek M. Head and
neck manifestations of erythema multiforme in
children. Otolaryngol Head Neck Surg. 1994;111:236-42.
https://doi.org/10.1177/01945998941113P112
PMid:8084631
|
|
|
|
|
6. Ragsdale AB, Barringer III TA, Anastasio GD. Alendronate
treatment to prevent osteoporotic fractures.
Ach Fam Med. 1998;7:583-6.
https://doi.org/10.1001/archfami.7.6.583
PMid:9821835
|
|
|
|
|
7. Biswas
PN, Wilton LV, Shakir
SA. Pharmacovigilance
study of alendronate
in England. Osteoporos Int. 2003;14:507-14.
https://doi.org/10.1007/s00198-003-1399-y
PMid:12730757
|
|
|
|
|
8. Auquier-Dunant
A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC, et al.
Severe cutaneous
adverse reactions. Correlations between
clinical patterns and causes of erythema multiforme majus,
Stevens-Johnson syndrome, and toxic
epidermal necrolysis:
results of an international prospective
study. Arch Dermatol. 2002;138:1019-24.
https://doi.org/10.1001/archderm.138.8.1019
PMid:12164739
|
|
|
|
|
9. Al-Johani
KA, Fedele S,
Porter SR. Erythema
multiforme
and related disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:642-54.
https://doi.org/10.1016/j.tripleo.2006.12.008
PMid:17344075
|
|
|
|
|
10. Sanchis JM, Bagán JV, Gavaldá C, Murillo J, Diaz JM. Erythema multiforme:
diagnosis, clinical manifestation and
treatment in a retrospective study of
22 patients. J Oral Pathol
Med. 2010;39:747-52.
https://doi.org/10.1111/j.1600-0714.2010.00912.x
PMid:20738747
|
|
|
|
|
11. Sokumbi
O, Wetter DA. Clinical features,
diagnosis, and treatment of erythema multiforme: a
review for the practicing
dermatologist. Int J Dermatol. 2012;51:889-902.
https://doi.org/10.1111/j.1365-4632.2011.05348.x
PMid:22788803
|
|
|
|
|
12. Samim
F, Auluck A,
Zed C, Williams PM. Erythema multiforme: a
review of the epidemiology,
pathogenesis, clinical features, and
treatment. Dent Clin
N Am. 2013;57:583-596.
https://doi.org/10.1016/j.cden.2013.07.001
PMid:24034067
|
|
|
|
|
13. French LE. Toxic epidermal necrolysis and
Stevens Johnson syndrome: our current
understanding. Allergol Int. 2006;55:9-16.
https://doi.org/10.2332/allergolint.55.9
PMid:17075281
|
|
|
|
|
14. Pereira
FA, Mudgil
AV, Rosmarim
DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56:181-200.
https://doi.org/10.1016/j.jaad.2006.04.048
PMid:17224365
|
|
|
|
|
15. Borchers
AT, Lee JL, Naguwa
SM, Cheema
GS, Gershwin ME. Stevens-Johnson
syndrome and toxic epidermal necrolysis. Autoimmunity Reviews. 2008;7:598-605.
https://doi.org/10.1016/j.autrev.2008.06.004
PMid:18603022
|
|